PolyNovo Limited (ASX:PNV)
Australia · Delayed Price · Currency is AUD | Market Cap | 711.57M -14.2% |
| Revenue (ttm) | 149.85M +16.4% |
| Net Income | 7.34M -44.4% |
| EPS | 0.01 -44.4% |
| Shares Out | 690.84M |
| PE Ratio | 98.10 |
| Forward PE | 67.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,914,277 |
| Open | 1.045 |
| Previous Close | 1.005 |
| Day's Range | 1.022 - 1.170 |
| 52-Week Range | 0.810 - 1.665 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 1.30 (+39.81%) |
| Earnings Date | Aug 26, 2026 |
About PolyNovo
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to tre... [Read more]
Financial Performance
In fiscal year 2026, PolyNovo's revenue was 149.85 million, an increase of 16.43% compared to the previous year's 128.70 million. Earnings were 7.34 million, a decrease of -44.45%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PNV stock is "Buy." The 12-month stock price target is $1.30, which is an increase of 39.81% from the latest price.
News
PolyNovo Earnings Call Transcript: H2 2026
Sales grew over 21% in constant currency, with strong gains in both U.S. and international markets. MTX sales nearly doubled, and adjusted EBITDA rose 50%. Strategic priorities for FY 2027 include regulatory milestones, new product launches, and further innovation investment.
PolyNovo Annual report: H2 2026
PolyNovo has published its H2 2026 annual report on August 25, 2026.
PolyNovo Earnings release: H2 2026
PolyNovo released its H2 2026 earnings on August 25, 2026, summarizing the period's financial results.
PolyNovo Slides: H2 2026
PolyNovo has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 25, 2026.
PolyNovo Earnings release: Trading update
PolyNovo released its earnings on July 22, 2026, summarizing the period's financial results.
PolyNovo Earnings Call Transcript: H1 2026
Group sales rose 26% to AUD 68.2 million, led by strong U.S. and international growth, with Adjusted EBITDA up 82%. Manufacturing capacity expanded, clinical evidence base strengthened, and new markets targeted for further acceleration.
PolyNovo Quarterly report: H1 2026
PolyNovo has published its H1 2026 quarterly earnings report on February 19, 2026.
PolyNovo Slides: H1 2026
PolyNovo has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 19, 2026.
PolyNovo Slides: Investor Presentation
PolyNovo has posted slides in relation to its latest quarterly earnings report, which was published on November 17, 2025.
PolyNovo Transcript: AGM 2025
The meeting highlighted strong financial growth, global expansion, and robust product innovation, while addressing governance reforms and executive turnover. Shareholders raised concerns about transparency and board changes, with new leadership and strategic initiatives positioned for future growth.